FindTrial
Sign In

An Expanded Access Study of Bemarituzumab (FPA144) for a Single Patient With Recurrent Bladder Cancer

An Expanded Access Study of Bemarituzumab (FPA144) for a Single Patient With Recurrent Bladder Cancer

Status
NO_LONGER_AVAILABLE
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT03801278
Acronym
FPA144
Enrollment
Unknown
Registered
2019-01-11
Start date
Unknown
Completion date
Unknown
Last updated
2021-12-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent Bladder Cancer

Keywords

Single patient

Brief summary

This is an open-label, expanded access protocol to continue administration of bemarituzumab (FPA144) in a single patient with recurrent bladder cancer

Detailed description

This protocol is intended to provide access to bemarituzumab (FPA144 an investigational agent) to a single patient with recurrent bladder cancer who had a response to study drug on FPA144-001. That study is closing and this expanded access protocol allows this single patient to continue receiving this agent.

Interventions

DRUGFPA144

Bemarituzumab administration every two weeks

Sponsors

Five Prime Therapeutics, Inc.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
MALE
Age
18 Years to No maximum

Inclusion criteria

1. Understand and sign an Institutional Review Board-approved informed consent form prior to receiving bemarituzumab 2. Previously enrolled on the FPA144-001 study, received bemarituzumab and obtained clinical benefit from the investigational product (IP) administration

Exclusion criteria

1\. Pregnancy and lactation

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026